The Voltage-Gated Calcium Channel Collective (VGCCC) is a global, multi-stakeholder initiative accelerating scientific understanding, clinical development and care for individuals affected by rare voltage-gated calcium channel (VGCC) disorders.

These conditions—often severe, multisystem and underdiagnosed—span a spectrum of neurological, cardiac and neurodevelopmental challenges. While individually rare, they share biological mechanisms, clinical overlap and opportunities for cross-gene therapeutic strategies.

The VGCCC connects patient-led organisations, clinicians, researchers and industry partners across gene-specific communities to:

Promote awareness of calcium channelopathies in clinical and research settings

Facilitate cross-gene learning to inform diagnosis, care standards and treatment development

Provide lived-experience insights that enhance trial design, outcome measures and patient engagement

Encourage strategic collaboration to unlock scalable, cross-cutting solutions in precision medicine

Current genes represented include:
CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S

The VGCCC offers a unique platform for drug developers and translational researchers seeking deeper access to patient communities, real-world insights and partnerships that accelerate meaningful innovation in rare ion channel disorders.

To learn more or explore collaboration, visit thevgccc.org.

The VGCCC

This department conducts research and analysis on genetic variations and their implications.

The VGCCC

Org chart

Teams

Genetic Research

Offices

The VGCCC

Org chart

Teams

Genetic Research

Offices

Related companies